Royalty Report: Drugs, Pain, Pharmaceuticals – Collection: 5409


Curated Royalty Rate Report
Created On: 2020-07-15, Record Count: 5


This collection of transactions and supporting information was developed using our AI algorithm to curate similar royalty reports into a cohesive collection to support your licensing, transfer pricing or other transaction scenarios where documented royalty rates and/or deal terms are important.
Created On: 2020-07-15
Record Count: 5

Primary Industries

  • Drugs
  • Pain
  • Pharmaceuticals
  • Personal Care Products

IPSCIO Report Record List

Below you will find the records curated into this collection.  This summary includes the complete licensed property description so that you can review and determine if this collection covers the topics, technology or transaction type that is relevant for your needs.  The full report will include all relevant deal data such as the royalty base, agreement date, term description, royalty rates and other deal terms.  For reference, here is a sample of a full IPSCIO curated royalty rate report: Sample Report

IPSCIO Record ID: 5409

License Grant
The Licensor grants an exclusive license to the Licensee to develop and commercialize a variety of biologically active compounds and has patented Know-How for generating chemical compounds having ion channel modulatory properties– used in medicinal chemistry programs.
Field of Use
Field of use shall mean the area of Pain, Pain Management, and all therapeutic, diagnostic or prophylactic uses of Agreement Compounds or any Derivatives thereof as Pain modulators,     including but not limited to, local, topical and/or systemic analgesics and/or anesthetics.

IPSCIO Record ID: 256269

License Grant
Licensor grants an exclusive license, with the right to grant sublicenses under the Licensor Licensed Patents and Patents within the Licensor Improvements to make, have made, develop, use, sell, offer for sale, have sold, and import Licensed Products in and for the Field throughout the Territory.
License Property
Licensor has certain patent rights relating to methods and compositions for use in the topical treatment of back pain, muscle tensions and myo-fascial pain, where such methods and compositions feature a topical carrier system containing a local anesthetic agent and are intended for use on intact mammalian skin and/or outer synovial membranes, and certain additional patent rights relating to methods and compositions that include the use of certain intradermal pharmaceutical penetration enhancing excipients.

“Licensed Product” means a transdermal pharmaceutical patch product for sale only by prescription containing bupivacaine as the only active ingredient, indicated and approved by a Regulatory Authority for use in the Field, wherein such product and/or indication is covered by a Valid Claim of the EpiCept Licensed Patents or a Valid Claim of a Patent under the EpiCept Improvements.

Field of Use
The Field shall mean all pharmaceutical applications for the palliative, prophylactic and/or therapeutic treatment of Back Pain in humans.

IPSCIO Record ID: 5728

License Grant
We entered into a non-exclusive, worldwide license agreement with Licensor, an individual,  for U.S. Provisional Patent Application No. 60/006,385 and U.S. Utility Patent Application No. 08/746,207 (U.S. Patent No. 6,248,788) directed to methods of treating neuropathic pain using capsaicin anesthetic, and all applications and patents relating thereto. The licensed technology relates to the use of capsaicin for pain relief. The primary patent underlying the license expires on November 6, 2016. This license agreement makes reference to the August 2001 license agreement between us and Drs. Campbell and Licensor and Mr. Meyer and provides that if Dr. Licensor develops or has any right to any technology under U.S. Patent No. 6,248,788 relating to an injectable product or service using capsaicin and its analogues for pain relief, the technology will be licensed to us pursuant to the terms of the August 2001 license agreement with Drs. Campbell and Licensor and Mr. Meyer.
Field of Use
Field of Use means any human or non-human diagnostic, prophylactic or therapeutic use of the Licensed Patents and Licensed Technology.

IPSCIO Record ID: 27204

License Grant
The Licensor entered into an agreement with an undisclosed Licensee a director of the Company, whereby the Licensor granted the Licensee a non-exclusive right to make, import and use the Licensee's product, Esterom®, under the Licensor's licensed patents and to use the Licensee's confidential information to develop new products that contain the same active ingredients as Esterom®, but are formulated differently.
License Property
Esterom is an investigational drug being studied as a topical analgesic. Chemically, it is a mixture of compounds derived from the esterification of cocaine in propylene glycol.
Field of Use
Esterom®, a topically applied compound for the treatment of impaired range of motion associated with acute lower back sprain and acute painful shoulder.

IPSCIO Record ID: 293157

License Grant
The Israeli Licensor, the technology transfer company of the University, granted Licensee a worldwide exclusive license to develop and commercialize certain patents, know-how and research results (collectively, the 2018 Hebrew Licensed Technology), in order to develop, manufacture, market, distribute or sell products, all within the use of the 2018 Hebrew Licensed Technology.
License Property
Licensor will undertake research and to synthesize chemical compounds that will be used by Licensee, through additional research at two Universities, to develop orally active analgesic and anti-inflammatory medications. Compounds will be shipped from University to Oxford for use in pre-clinical studies to establish efficacy in pain and inflammation.
Field of Use
This agreement pertains to the drug industry for the treatment of any and all veterinary and human medical conditions, including obesity, pain, inflammation and arthritis (the 2018 Field).
Disclaimer: The information gathered from RoyaltySource® database was sourced from the U.S. Securities and Exchange Commission EDGAR Filings and other public records. While we believe the sources to be reliable, this does not guarantee the accuracy or completeness of the information provided. Further, the information is supplied as general guidance and is not intended to represent or be a substitute for a detailed analysis or professional judgment. This information is for private use only and may not be resold or reproduced without permission.